

# World Journal of *Clinical Cases*

*World J Clin Cases* 2022 September 26; 10(27): 9550-9969



## Contents

Thrice Monthly Volume 10 Number 27 September 26, 2022

### OPINION REVIEW

- 9550** Psychiatric disorders and pain: The recurrence of a comorbidity  
*Vyshka G*

### REVIEW

- 9556** Cardiovascular disease and COVID-19, a deadly combination: A review about direct and indirect impact of a pandemic  
*Vidal-Perez R, Brandão M, Pazdernik M, Kresoja KP, Carpenito M, Maeda S, Casado-Arroyo R, Muscoli S, Pöss J, Fontes-Carvalho R, Vazquez-Rodriguez JM*
- 9573** Molecular factors, diagnosis and management of gastrointestinal tract neuroendocrine tumors: An update  
*Pavlidis ET, Pavlidis TE*

### MINIREVIEWS

- 9588** Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation  
*Leowattana W, Leowattana T, Leowattana P*
- 9602** COVID-19 and the cardiovascular system-current knowledge and future perspectives  
*Chatzis DG, Magounaki K, Pantazopoulos I, Bhaskar SMM*

### ORIGINAL ARTICLE

#### Case Control Study

- 9611** PDCA nursing in improving quality management efficacy in endoscopic submucosal dissection  
*He YH, Wang F*

#### Retrospective Study

- 9619** Impact of COVID-19 pandemic on the ocular surface  
*Marta A, Marques JH, Almeida D, José D, Sousa P, Barbosa I*
- 9628** Anatomy and clinical application of suprascapular nerve to accessory nerve transfer  
*Wang JW, Zhang WB, Li F, Fang X, Yi ZQ, Xu XL, Peng X, Zhang WG*
- 9641** Therapeutic effect of two methods on avulsion fracture of tibial insertion of anterior cruciate ligament  
*Niu HM, Wang QC, Sun RZ*
- 9650** Efficacy of transcatheter arterial chemoembolization using pirarubicin-loaded microspheres combined with lobaplatin for primary liver cancer  
*Zhang C, Dai YH, Lian SF, Liu L, Zhao T, Wen JY*

- 9657** Prognostic significance of sex determining region Y-box 2, E-cadherin, and vimentin in esophageal squamous cell carcinoma

*Li C, Ma YQ*

- 9670** Clinical characteristics and prognosis of orbital solitary fibrous tumor in patients from a Chinese tertiary eye hospital

*Ren MY, Li J, Wu YX, Li RM, Zhang C, Liu LM, Wang JJ, Gao Y*

### Observational Study

- 9680** Altered heart rate variability and pulse-wave velocity after spinal cord injury

*Tsou HK, Shih KC, Lin YC, Li YM, Chen HY*

- 9693** Intra and extra pelvic multidisciplinary surgical approach of retroperitoneal sarcoma: Case series report

*Song H, Ahn JH, Jung Y, Woo JY, Cha J, Chung YG, Lee KH*

### META-ANALYSIS

- 9703** Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer

*Li ZH, Ma YJ, Jia ZH, Weng YY, Zhang P, Zhu SJ, Wang F*

- 9714** Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review

*Cao JX, You J, Wu LH, Luo K, Wang ZX*

### CASE REPORT

- 9727** Treatment of gastric cancer with dermatomyositis as the initial symptom: Two case reports and review of literature

*Sun XF, Gao XD, Shen KT*

- 9734** Gallbladder hemorrhage—An uncommon surgical emergency: A case report

*Valenti MR, Cavallaro A, Di Vita M, Zanghi A, Longo Trischitta G, Cappellani A*

- 9743** Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report

*Zhu SG, Li HB, Dai TX, Li H, Wang GY*

- 9750** Myocarditis as an extraintestinal manifestation of ulcerative colitis: A case report and review of the literature

*Wang YY, Shi W, Wang J, Li Y, Tian Z, Jiao Y*

- 9760** Endovascular treatment of traumatic renal artery pseudoaneurysm with a Stanford type A intramural haematoma: A case report

*Kim Y, Lee JY, Lee JS, Ye JB, Kim SH, Sul YH, Yoon SY, Choi JH, Choi H*

- 9768** Histiocytoid giant cellulitis-like Sweet syndrome at the site of sternal aspiration: A case report and review of literature

*Zhao DW, Ni J, Sun XL*

- 9776** Rare giant corneal keloid presenting 26 years after trauma: A case report  
*Li S, Lei J, Wang YH, Xu XL, Yang K, Jie Y*
- 9783** Efficacy evaluation of True Lift®, a nonsurgical facial ligament retightening injection technique: Two case reports  
*Huang P, Li CW, Yan YQ*
- 9790** Synchronous primary duodenal papillary adenocarcinoma and gallbladder carcinoma: A case report and review of literature  
*Chen J, Zhu MY, Huang YH, Zhou ZC, Shen YY, Zhou Q, Fei MJ, Kong FC*
- 9798** Solitary fibrous tumor of the renal pelvis: A case report  
*Liu M, Zheng C, Wang J, Wang JX, He L*
- 9805** Gastric metastasis presenting as submucosa tumors from renal cell carcinoma: A case report  
*Chen WG, Shan GD, Zhu HT, Chen LH, Xu GQ*
- 9814** Laparoscopic correction of hydronephrosis caused by left paraduodenal hernia in a child with cryptorchism: A case report  
*Wang X, Wu Y, Guan Y*
- 9821** Diagnosed corrected transposition of great arteries after cesarean section: A case report  
*Ichii N, Kakinuma T, Fujikawa A, Takeda M, Ohta T, Kagimoto M, Kaneko A, Izumi R, Kakinuma K, Saito K, Maeyama A, Yanagida K, Takeshima N, Ohwada M*
- 9828** Misdiagnosis of an elevated lesion in the esophagus: A case report  
*Ma XB, Ma HY, Jia XF, Wen FF, Liu CX*
- 9834** Diagnostic features and therapeutic strategies for malignant paraganglioma in a patient: A case report  
*Gan L, Shen XD, Ren Y, Cui HX, Zhuang ZX*
- 9845** Infant with reverse-transcription polymerase chain reaction confirmed COVID-19 and normal chest computed tomography: A case report  
*Ji GH, Li B, Wu ZC, Wang W, Xiong H*
- 9851** Pulmonary hypertension secondary to seronegative rheumatoid arthritis overlapping antisynthetase syndrome: A case report  
*Huang CY, Lu MJ, Tian JH, Liu DS, Wu CY*
- 9859** Monitored anesthesia care for craniotomy in a patient with Eisenmenger syndrome: A case report  
*Ri HS, Jeon Y*
- 9865** Emergency treatment and anesthesia management of internal carotid artery injury during neurosurgery: Four case reports  
*Wang J, Peng YM*

- 9873** Resolution of herpes zoster-induced small bowel pseudo-obstruction by epidural nerve block: A case report  
*Lin YC, Cui XG, Wu LZ, Zhou DQ, Zhou Q*
- 9879** Accidental venous port placement *via* the persistent left superior vena cava: Two case reports  
*Zhou RN, Ma XB, Wang L, Kang HF*
- 9886** Application of digital positioning guide plates for the surgical extraction of multiple impacted supernumerary teeth: A case report and review of literature  
*Wang Z, Zhao SY, He WS, Yu F, Shi SJ, Xia XL, Luo XX, Xiao YH*
- 9897** Iatrogenic aortic dissection during right transradial intervention in a patient with aberrant right subclavian artery: A case report  
*Ha K, Jang AY, Shin YH, Lee J, Seo J, Lee SI, Kang WC, Suh SY*
- 9904** Pneumomediastinum and subcutaneous emphysema secondary to dental extraction: Two case reports  
*Ye LY, Wang LF, Gao JX*
- 9911** Hemorrhagic shock due to submucosal esophageal hematoma along with mallory-weiss syndrome: A case report  
*Oba J, Usuda D, Tsuge S, Sakurai R, Kawai K, Matsubara S, Tanaka R, Suzuki M, Takano H, Shimoizawa S, Hotchi Y, Usami K, Tokunaga S, Osugi I, Katou R, Ito S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Nomura T, Sugita M*
- 9921** Concurrent severe hepatotoxicity and agranulocytosis induced by *Polygonum multiflorum*: A case report  
*Shao YL, Ma CM, Wu JM, Guo FC, Zhang SC*
- 9929** Transient ischemic attack after mRNA-based COVID-19 vaccination during pregnancy: A case report  
*Chang CH, Kao SP, Ding DC*
- 9936** Drug-induced lung injury caused by acetaminophen in a Japanese woman: A case report  
*Fujii M, Kenzaka T*
- 9945** Familial mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episode syndrome: Three case reports  
*Yang X, Fu LJ*
- 9954** Renal pseudoaneurysm after rigid ureteroscopic lithotripsy: A case report  
*Li YH, Lin YS, Hsu CY, Ou YC, Tung MC*

**LETTER TO THE EDITOR**

- 9961** Role of traditional Chinese medicine in the initiative practice for health  
*Li Y, Li SY, Zhong Y*
- 9964** Impact of the COVID-19 pandemic on healthcare workers' families  
*Helou M, El Osta N, Husni R*

- 9967** Transition beyond the acute phase of the COVID-19 pandemic: Need to address the long-term health impacts of COVID-19

*Tsioutis C, Tofarides A, Spernovasilis N*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Yusuf Tutar, PhD, Chairman, Director, Full Professor, Department of Basic Pharmaceutical Sciences, Division of Biochemistry, University of Health Sciences, Istanbul 34668, Turkey. ytutar@outlook.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jin-Lei Wang*.

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Thrice Monthly

**EDITORS-IN-CHIEF**

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

**PUBLICATION DATE**

September 26, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Transient ischemic attack after mRNA-based COVID-19 vaccination during pregnancy: A case report

Chi-Han Chang, Sheng-Po Kao, Dah-Ching Ding

**Specialty type:** Medicine, general and internal

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): C, C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** He Z, China; Rotondo JC, Italy; Tolunay HE, Turkey

**Received:** May 23, 2022

**Peer-review started:** May 23, 2022

**First decision:** July 12, 2022

**Revised:** July 19, 2022

**Accepted:** August 11, 2022

**Article in press:** August 11, 2022

**Published online:** September 26, 2022



**Chi-Han Chang, Sheng-Po Kao, Dah-Ching Ding**, Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan

**Corresponding author:** Dah-Ching Ding, PhD, Chief Physician, Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, 707, Sec. 3, Chung-Yang Road, Hualien 970, Taiwan. [dah1003@yahoo.com.tw](mailto:dah1003@yahoo.com.tw)

### Abstract

#### BACKGROUND

Thrombocytopenia with thrombosis syndrome has been reported after vaccination against severe acute respiratory syndrome coronavirus 2 with two mRNA vaccines. The syndrome is characterized by thrombosis, especially cerebral venous sinus thrombosis, and may lead to stroke. Pregnant women with stroke show higher rates of pregnancy loss and experience serious pregnancy complications. We present the case of a 24-year-old pregnant woman with a transient ischemic attack (TIA) that developed after vaccination with the Moderna mRNA-1273 vaccine (at 37 2/7 wk).

#### CASE SUMMARY

TIA occurred 13 d following the coronavirus disease vaccination. At 39 1/7 wk of pregnancy, the patient presented with sudden onset of right eye blurred vision with headache, dizziness with nausea, right-hand weakness, anomia, and alexia. The symptoms lasted 3 h; TIA was diagnosed. Blood test results revealed elevated D-dimer, cholesterol, and triglyceride levels. Brain magnetic resonance imaging showed no acute hemorrhagic or ischemic stroke. At pregnancy 37 6/7 wk, she was admitted for cesarean delivery to reduce subsequent risk of stroke during labor. Body mass index on admission was 19.8 kg/m<sup>2</sup>. Magnetic resonance angiography and transesophageal echocardiography showed no abnormalities. The next day, a mature female baby weighing 2895 g and measuring 50 cm was delivered. Apgar scores were 8 and 9 in the first and fifth minutes. D-dimer levels decreased on postoperative day 4. After discharge, the autoimmune panel was within normal limits, including antinuclear and antiphospholipid antibodies.

#### CONCLUSION

TIA might be developed after the mRNA vaccines in pregnant women.

**Key Words:** Pregnancy; mRNA vaccine; COVID-19; Stroke; Transient ischemic attack;



## Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** We reported the information of transient ischemic attack following coronavirus disease 2019 (COVID-19) mRNA vaccination in a pregnant woman. We also updated the information on vaccine-induced thrombosis caused by COVID-19 mRNA vaccination. Finally, since transient ischemic attack is a rare event associated with COVID-19 mRNA vaccination, vaccination should not be prohibited for pregnant women.

**Citation:** Chang CH, Kao SP, Ding DC. Transient ischemic attack after mRNA-based COVID-19 vaccination during pregnancy: A case report. *World J Clin Cases* 2022; 10(27): 9929-9935

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i27/9929.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v10.i27.9929>

## INTRODUCTION

Transient ischemic attack (TIA) is categorized as the transient appearance of focal neurological abnormalities and disappearance within 24 h, including sensory changes, weakness, and cranial nerve abnormalities[1]. TIA is preceded in approximately 15% of strokes[1]. Stroke, a devastating complication during pregnancy, occurs in approximately 30 per 100000 pregnancies[2]. The causes of stroke include embolism, thrombi, atherosclerotic diseases, and hypotension[1]. Pregnant women with stroke show higher rates of pregnancy loss and experience serious complications[3].

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) has been a pandemic since late 2019 and has caused over 554 million and 6.35 million deaths to date [4]. In diagnosing COVID-19, real time-polymerase chain reaction (PCR)-based assays is the gold-standard method for detecting viral RNA in nasopharyngeal samples[4]. Other diagnostic modalities under development include droplet digital PCR, clustered regularly interspaced short palindromic repeats, and next-generation sequencing[4].

COVID-19 is associated with maternal coagulopathy[5]. It can also induce disseminated intravascular coagulopathy and thrombosis[6]. COVID-19 has also been associated with coagulation disorders, secondary bacterial infections, immunodeficiency, and myocardial injury[4]. In Taiwan, two mRNA vaccines (Moderna mRNA-1273 and Pfizer-BioNTech BNT162b2) are presently available for immunization, and no harmful effects have been reported in pregnant women[7].

Nevertheless, thrombocytopenia with thrombosis syndrome (TTS) has been reported after vaccination against SARS-CoV-2 with two mRNA vaccines[8]. The syndrome is characterized by thrombosis, especially cerebral venous sinus thrombosis (CVST), and may lead to stroke[9]. Two meta-analyses presented the pros and cons of COVID-19 vaccination regarding vaccine-induced immune thrombotic thrombocytopenia (VITT)[10,11]. In addition to reports of TTS, a few cases of CVST were also reported after vaccination with mRNA-based vaccines[8,12-14].

Here, we report the case of a 24-year-old pregnant woman with a TIA that developed after vaccination with the Moderna mRNA-1273 vaccine.

## CASE PRESENTATION

### Chief complaints

A 24-year-old pregnant (39 1/7 wk) woman presented to our hospital emergency room (ER) with sudden onset of right eye blurred vision with headache, dizziness with nausea, right-hand weakness, anomia, and alexia. These symptoms lasted approximately 3 h.

### History of present illness

She received the first dose of the mRNA-1273 vaccine 13 d before the onset of the symptoms (pregnancy at 37 2/7 wk). PCR testing for SARS-CoV-2 was not detectable.

### History of past illness

She denied systemic diseases such as chronic hypertension, type 2 diabetes mellitus, previous cardiovascular disease, or a history of autoimmune disease, thrombophilia, or leukemia.

**Personal and family history**

A family history of stroke and TIA was ruled out.

**Physical examination**

At the ER, an ophthalmologist was consulted due to blurred vision, and no abnormality was noted. She was discharged after her condition improved without any treatment.

On the next day, she followed up at the Obstetrics outpatient department. The ultrasonography revealed an estimated fetal bodyweight of 2600 g and adequate amniotic fluid. No placental abruption or other anomaly was observed.

**Laboratory examinations**

At the neurology department (pregnancy at 39 5/7 wk), a blood test revealed an elevated D-dimer level (2082.56 ng/mL) and hyperlipidemia [low-density lipoprotein 197 mg/dL (normal 100 mg/dL), total cholesterol 309 mg/dL (normal < 200 mg/dL), triglycerides 476 mg/dL (normal < 150 mg/dL)]. The coagulation profile (prothrombin time, activated partial thromboplastin time, and platelet level) and kidney and liver functions were within normal ranges (Table 1). Brain magnetic resonance imaging (MRI) showed no acute hemorrhagic or ischemic stroke.

She was admitted to our ward for further evaluation of TIA and scheduled to receive a cesarean section (C/S) to lower the risk of stroke during labor (pregnancy at 39 6/7 wk). The blood pressure on admission was 126/77 mmHg. Her body mass index (BMI) was 19.8 kg/m<sup>2</sup>.

**Imaging examinations**

On admission, magnetic resonance angiography (MRA) of the neck showed no stenosis (> 90%) of either the extracranial internal carotid arteries or the common carotid arteries. Transesophageal echocardiography (TEE) revealed no thrombus formation, notable vegetation, or evidence of right-to-left shunt flow *via* a patent foramen ovale. Fetal monitoring showed a fetal heartbeat of 110-145 bpm with moderate variability and intermittent uterine contraction.

---

**FINAL DIAGNOSIS**

---

Pregnancy 39 6/7 wk with TIA.

---

**TREATMENT**

---

On the next day, C/S was performed (pregnancy at 40 wk). The estimated blood loss volume was 300 mL. A female baby with a bodyweight of 2895 g was delivered smoothly. The Apgar scores were 8 and 9 at 1 and 5 min after birth, respectively. The D-dimer level was 3769.14 ng/mL before surgery.

After C/S, there was no active bleeding during hospitalization, and the surgical wound was clean. D-dimer levels decreased to 1759.38 ng/mL on postoperative day 4. The patient was discharged in stable condition.

---

**OUTCOME AND FOLLOW-UP**

---

After discharge, she was followed up at the neurology department, and the autoimmune panel, including antinuclear and antiphospholipid antibodies, was within normal limits.

---

**DISCUSSION**

---

This patient met the diagnostic criteria for TIA, including duration of symptoms (< 24 h), sudden onset of a focal neurologic symptom, and a transient episode of neurological dysfunction caused by focal ischemia of the brain, spinal cord, or retina without evidence of acute infarction on neuroimaging[15]. TIA is preceded in 15% of patients with stroke[1].

The possible mechanisms for TIA include large-artery atherosclerosis, emboli from an extracranial artery or the heart, lacunar or small vessel occlusion, hematologic disorders such as sickle cell anemia, illicit drug use, such as cocaine or amphetamines, or Moyamoya disease[16]. However, in our case report, the patient was only a risk factor for atherosclerosis (presented as hyperlipidemia) but was otherwise healthy (normal BMI and blood pressure, serum sampling, brain MRI, neck MRA, and TEE all showed negative findings). Since the patient presented with TIA 13 d after receiving the first dose of the mRNA vaccination, the TIA was most likely caused by the vaccine.

**Table 1 Summary of laboratory results for this patient**

Laboratory studies	Results (reference value)
Polymerase chain reaction test for SARS-CoV-2 virus using a nasopharyngeal swab	Undetectable
Platelet count nadir, $\times 10^3$ cells/ $\mu$ L	185 (150-400)
D-dimer peak, ng/mL	5351.22 (0-499)
Activated partial thromboplastin time peak, s	26.5 (23.9-35.5)
Prothrombin time, s	10.3 (8-12)
Anticardiolipin antibody level	4.69 $\pm$ 1.29
IgG, GPL	< 1.6 (0-19.9)
IgM, MPL	4.9 (0-12.5)
B2-glycoprotein 1 class	
IgG, SGU	< 1.4 (0-19.9)
IgM, SMU	0.9 (0-20)
Antinuclear antibodies	
Homogeneous, speckled, centromere, nucleolar, granular	< 1:40 (1:40)
Anti-thyroglobulin antibodies, IU/mL	< 0.9 (0-4)
Anti-thyroid peroxidase antibodies, IU/mL	< 0.25 (0-9)
Total cholesterol, mg/dL	309 (0-200)
Triglyceride, mg/dL	476 (0-150)
Low-density lipoprotein cholesterol, mg/dL	197 (0-100)
Glycated hemoglobin A1C, %	5.1 (4-6)
Magnetic resonance imaging of the brain	No signs of ischemic stroke
Magnetic resonance angiography of the neck	No stenosis (> 90%) of both extracranial ICAs and CCAs
Transesophageal echocardiography	No thrombus formation, no notable vegetations, and no pathological shunt

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; GPL: IgG phospholipid units; MPL: IgM phospholipid units; SGU: Standard IgG units; SMU: Standard IgM units; ICAs: Internal carotid arteries; CCAs: Common carotid arteries.

Among the complications associated with COVID-19 vaccines, TTS associated with adenovirus vector vaccines is the most common[8]. Adenovirus vector VITT is characterized by the production of antibodies against platelet factor-4, thrombosis at unusual sites such as CVST[17], and pathogenesis similar to that of heparin-induced thrombocytopenia.

Kim *et al*[10] meta-analyzed thrombosis pattern and clinical outcome of COVID-19 VITT. Eighteen studies were included and showed that the incidence of VITT after ChAdOx1 nCoV-19 vaccination was 28 per 100000 doses. In a total of 664 patients analyzed, the mean age was 45.6 years, and females were predominant (70%). Splanchnic vein thrombosis, deep vein thrombosis/pulmonary embolism, and CVST happened in 19%, 36%, and 54% of patients with VITT, respectively. One-third of patients with VITT had a fatal outcome[10]. They concluded that clinicians should identify VITT early to improve outcomes of management. Another meta-analysis recruited corresponding literature regarding adverse events (AE) of COVID-19 vaccination published from January 1, 2020 to October 20, 2021[11]. Fifty-three studies were subjected to the analysis. The incidence of vascular events was higher in viral vector vaccination than in mRNA vaccination. The incidence of AE was higher in females, older people, and after the second dose. They concluded that the safety of the COVID-19 vaccination was acceptable.

Kakovan *et al*[18] reported a literature review of stroke associated with COVID-19 vaccination. They found most patients with stroke after vaccination were females under the age of 60 years and had received the ChAdOx1 nCoV-19 vaccine. The clinical course of CVST associated with COVID-19 vaccination was more severe than that without associated with vaccination. Low-molecular-weight heparin is commonly used to treat CVST. High-dose glucocorticoids and intravenous immunoglobulin may have varying success rates in treating CVST. The French population study recruited 3.9 million persons who received one dose of the BNT162b2 vaccine and 3.2 million persons who received two doses[19]. The incidence of myocardial infarction, stroke, and pulmonary embolism was not increased

within 14 d of vaccination[19]. The study recruited nursing home residents in the US and found no major AE after the first or second dose of the vaccine[20]. The previous cohort study found an increased risk of myocarditis and pericarditis after COVID-19 mRNA vaccination. Men aged 18-25 years have the highest risk after a second dose of the vaccine. Therefore, the pathogenesis of VITT should be studied and diagnosed early to prevent unfavorable outcomes.

Additionally, the occurrence of cerebrovascular diseases following mRNA-based COVID-19 vaccination has been reported[8,12-14]. Sangli *et al*[8] reported the case of a 65-year-old man with hypertension and hyperlipidemia who developed severe thrombocytopenia (14000 cells/ $\mu$ L), acute pulmonary embolism, and deep vein thrombosis in both lower extremities 10 d after receiving a second dose of the mRNA-1273 vaccine. Inferior vena cava filters were placed, and platelet transfusions and intravenous immunoglobulin, followed by intravenous dexamethasone, were administered for presumed immune-mediated thrombocytopenia. Enzyme-linked immunosorbent assay for antiplatelet factor 4/heparin IgG was strongly positive, consistent with the VITT mechanism for venous thromboembolism. The patient developed CVST, continued to deteriorate, and died eventually[8].

Krzywicka *et al*[12] reported 213 post-vaccination CVST cases, among which 187 patients received AZD1222 vaccination, and 26 received mRNA vaccination (25 with Pfizer/BioNTech, BNT162b2 and one with Moderna, mRNA-1273). Thrombocytopenia was reported in 107/187 CVST cases (57%) in the AZD1222 group, none in the mRNA vaccine group (0%), and 7/100 (7%) in the pre-COVID-19 CVST group[12], suggesting that mRNA vaccination rarely induces CVST.

Yoshida *et al*[13] reported the case of an 83-year-old Japanese woman with persistent atrial fibrillation receiving rivaroxaban treatment without symptomatic ischemic strokes for 10 years, who developed repeated cardioembolic strokes three days after each of the two doses of vaccination with the BNT162b2 (Pfizer) COVID-19 mRNA vaccine. Thrombocytopenia and hyperlipidemia were not observed. PCR tests for SARS-CoV-2 and antibodies for platelet factor 4 were not performed. However, it is difficult to exclude the possibility of COVID-19 mRNA vaccine-induced ischemic stroke since the stroke occurred twice 3 d after receiving each dose of mRNA vaccine in this patient with no previous history of symptomatic ischemic strokes. Therefore, caution may be needed in patients who experience a stroke soon after the first dose[13].

Yousaf *et al*[14] reported the case of a 57-year-old female who presented with extensive lower limb superficial and deep thrombosis three weeks after the second dose of BNT162b2. Her D-dimer level was above 35.2 mg/L. Due to suspicions of DVT, a Doppler ultrasound showed left lower limb vein thrombosis extending up to the inferior vena cava. She received enoxaparin for 2 d, followed by rivaroxaban. After 3 mo of follow-up, she was well and continued anticoagulation medication for 6 mo [14].

Taken together, after COVID-19 mRNA vaccination, thrombocytopenia is rarely developed. The cause of developing stroke after mRNA vaccination needs to be elucidated in further studies. Our case experienced TIA post-vaccination with the mRNA vaccine, given the lack of underlying diseases and risk factors, except hyperlipidemia and pregnancy. Antiplatelet factor 4 checks in the future may confirm the diagnosis.

## CONCLUSION

TIA might develop after COVID-19 mRNA vaccination. However, very few cases of TIA have been reported in these recipients. Therefore, this rare event is outweighed by the benefits of these vaccines and should not prevent pregnant women from receiving mRNA-based COVID-19 vaccines.

## FOOTNOTES

**Author contributions:** Ding DC, Kao SP, and Chang CH designed the research study; Ding DC, Chang CH performed the research; Ding DC and Chang CH analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.

**Informed consent statement:** A written informed consent was obtained from the patient for publication of this case report.

**Conflict-of-interest statement:** The authors have nothing to disclose.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license

their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Taiwan

**ORCID number:** Dah-Ching Ding 0000-0001-5105-068X.

**S-Editor:** Wang DM

**L-Editor:** A

**P-Editor:** Wang DM

## REFERENCES

- 1 Grear KE, Bushnell CD. Stroke and pregnancy: clinical presentation, evaluation, treatment, and epidemiology. *Clin Obstet Gynecol* 2013; **56**: 350-359 [PMID: 23632643 DOI: 10.1097/GRF.0b013e31828f25fa]
- 2 Miller EC, Leffert L. Stroke in Pregnancy: A Focused Update. *Anesth Analg* 2020; **130**: 1085-1096 [PMID: 31124843 DOI: 10.1213/ANE.0000000000004203]
- 3 van Alebeek ME, de Vrijer M, Arntz RM, Maaijwee NAMM, Synhaeve NE, Schoonderwaldt H, van der Vlugt MJ, van Dijk EJ, de Heus R, Rutten-Jacobs LCA, de Leeuw FE. Increased Risk of Pregnancy Complications After Stroke: The FUTURE Study (Follow-Up of Transient Ischemic Attack and Stroke Patients and Unelucidated Risk Factor Evaluation). *Stroke* 2018; **49**: 877-883 [PMID: 29511129 DOI: 10.1161/STROKEAHA.117.019904]
- 4 Rotondo JC, Martini F, Maritati M, Caselli E, Gallenga CE, Guarino M, De Giorgio R, Mazziotta C, Tramarin ML, Badiale G, Tognon M, Contini C. Advanced Molecular and Immunological Diagnostic Methods to Detect SARS-CoV-2 Infection. *Microorganisms* 2022; **10** [PMID: 35744711 DOI: 10.3390/microorganisms10061193]
- 5 Graham M, Sproule C, Sharma M, Likinyo H, Glackin K, Hurrell D, Khalil A, Mone F. Spontaneous maternal coagulopathy in COVID-19. *Ultrasound Obstet Gynecol* 2022; **59**: 558-560 [PMID: 35025134 DOI: 10.1002/uog.24859]
- 6 Benhamou D, Keita H, Ducloy-Bouthors AS; Obstetric Anaesthesia and Critical Care Club Working Group. Coagulation changes and thromboembolic risk in COVID-19 obstetric patients. *Anaesth Crit Care Pain Med* 2020; **39**: 351-353 [PMID: 32437961 DOI: 10.1016/j.accpm.2020.05.003]
- 7 Collier AY, McMahan K, Yu J, Tostanoski LH, Aguayo R, Ansel J, Chandrashekar A, Patel S, Apraku Bondzie E, Sellers D, Barrett J, Sanborn O, Wan H, Chang A, Anioke T, Nkolola J, Bradshaw C, Jacob-Dolan C, Feldman J, Gebre M, Borducchi EN, Liu J, Schmidt AG, Suscovich T, Linde C, Alter G, Hacker MR, Barouch DH. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. *JAMA* 2021; **325**: 2370-2380 [PMID: 33983379 DOI: 10.1001/jama.2021.7563]
- 8 Sangli S, Virani A, Cheronis N, Vannatter B, Minich C, Noronha S, Bhagavatula R, Sperdelozzi D, Sareen M, Kaplan RB. Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine. *Ann Intern Med* 2021; **174**: 1480-1482 [PMID: 34181446 DOI: 10.7326/L21-0244]
- 9 See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, Durbin AP, Edwards K, Miller E, Harrington TA, Mba-Jonas A, Nair N, Nguyen DT, Talaat KR, Urrutia VC, Walker SC, Creech CB, Clark TA, DeStefano F, Broder KR. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. *JAMA* 2021; **325**: 2448-2456 [PMID: 33929487 DOI: 10.1001/jama.2021.7517]
- 10 Kim AY, Woo W, Yon DK, Lee SW, Yang JW, Kim JH, Park S, Koyanagi A, Kim MS, Lee S, Shin JI, Smith L. Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis. *Int J Infect Dis* 2022; **119**: 130-139 [PMID: 35339716 DOI: 10.1016/j.ijid.2022.03.034]
- 11 Chen L, Cai X, Zhao T, Han B, Xie M, Cui J, Zhang J, Wang C, Liu B, Lu Q, Cui F. Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis. *Vaccines (Basel)* 2022; **10** [PMID: 35455344 DOI: 10.3390/vaccines10040596]
- 12 Krzywicka K, Heldner MR, Sánchez van Kammen M, van Haaps T, Hiltunen S, Silvis SM, Levi M, Kremer Hovinga JA, Jood K, Lindgren E, Tatlisumak T, Putaala J, Aguiar de Sousa D, Middeldorp S, Arnold M, Coutinho JM, Ferro JM. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. *Eur J Neurol* 2021; **28**: 3656-3662 [PMID: 34293217 DOI: 10.1111/ene.15029]
- 13 Yoshida K, Tanaka K, Suto Y, Fukuda H. Repeated Cardioembolic Stroke after COVID-19 mRNA Vaccination: A Case Report. *J Stroke Cerebrovasc Dis* 2022; **31**: 106233 [PMID: 34883321 DOI: 10.1016/j.jstrokecerebrovasdis.2021.106233]
- 14 Yousef Z, Ata F, Mohammed Hammamy RA. Thrombosis post-mRNA-based SARS-CoV-2 vaccination (BNT162b2) – Time to think beyond thrombosis with thrombocytopenia syndrome (TTS). *thromb update* 2022; **7**: 100-104
- 15 Easton JD, Saver JL, Albers GW, Albers MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL; American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. *Stroke* 2009; **40**: 2276-2293 [PMID: 19423857 DOI: 10.1161/STROKEAHA.108.192218]
- 16 Boehme AK, Esenwa C, Elkind MS. Stroke Risk Factors, Genetics, and Prevention. *Circ Res* 2017; **120**: 472-495 [PMID: 28111111 DOI: 10.1161/CIRCRESAHA.117.308881]

- 28154098 DOI: [10.1161/CIRCRESAHA.116.308398](https://doi.org/10.1161/CIRCRESAHA.116.308398)]
- 17 **McGonagle D**, De Marco G, Bridgewood C. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. *J Autoimmun* 2021; **121**: 102662 [PMID: [34051613](https://pubmed.ncbi.nlm.nih.gov/34051613/) DOI: [10.1016/j.jaut.2021.102662](https://doi.org/10.1016/j.jaut.2021.102662)]
- 18 **Kakovan M**, Ghorbani Shirkouhi S, Zarei M, Andalib S. Stroke Associated with COVID-19 Vaccines. *J Stroke Cerebrovasc Dis* 2022; **31**: 106440 [PMID: [35339857](https://pubmed.ncbi.nlm.nih.gov/35339857/) DOI: [10.1016/j.jstrokecerebrovasdis.2022.106440](https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106440)]
- 19 **Jabagi MJ**, Botton J, Bertrand M, Weill A, Farrington P, Zureik M, Dray-Spira R. Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. *JAMA* 2022; **327**: 80-82 [PMID: [34807248](https://pubmed.ncbi.nlm.nih.gov/34807248/) DOI: [10.1001/jama.2021.21699](https://doi.org/10.1001/jama.2021.21699)]
- 20 **Bardenheier BH**, Gravenstein S, Blackman C, Gutman R, Sarkar IN, Feifer RA, White EM, McConeghy K, Nanda A, Mor V. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. *Vaccine* 2021; **39**: 3844-3851 [PMID: [34092431](https://pubmed.ncbi.nlm.nih.gov/34092431/) DOI: [10.1016/j.vaccine.2021.05.088](https://doi.org/10.1016/j.vaccine.2021.05.088)]





Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

